ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Free serum testosterone versus total testosterone as surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Lucas Regis presented an institutional series on whether free serum testosterone (FT) or total testosterone (TT) can be a surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients. The mean follow up for their study was 107 months (range: 22-304 months). A total of 36 patients (49.3%) developed castration resistance (CR), 15 patients (20.5%) developed metastatic spread, and 6 patients (9.2%) died of disease. From 73 patients who were on LHRH agonist for at least 12 months, they obtained TT (chemiluminescent assay-lower sensitivity 10 nd/dL) and FT (analogue ligand radioimmunoassay-lower sensitivity 0.05 pg/mL). In order to establish the castration level of FT with clinical impact, survival analysis using 50, 32 and 20 ng/dL for TT, and 1.7, 1.1 and 0.7 pg/mL for FT was performed.

auaOn multivariable analysis, FT (OR=4.33, p <0.001) and Gleason score (OR=2.73, p < 0.005) were the two independent predictors of survival, independent of CR. Dr. Regis reported that any TT threshold demonstrated significant differences for survival. In comparison, FT of 1.1 pg/mL was the lower threshold and showed significant differences in survival free of CR. The active form of testosterone (FT) represents 2% of TT while 40% is bound to SHBG and 58% to albumin.

In this study, authors show that in comparison to TT, FT is a better surrogate marker of CR in patients who are receiving LHRH agonist.

Presented by Lucas Regis at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Barcelona, Spain

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe